220 related articles for article (PubMed ID: 37263896)
1. Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer.
González-Martín A; Pothuri B; Vergote I; Graybill W; Lorusso D; McCormick CC; Freyer G; Backes F; Heitz F; Redondo A; Moore RG; Vulsteke C; O'Cearbhaill RE; Malinowska IA; Shtessel L; Compton N; Mirza MR; Monk BJ
Eur J Cancer; 2023 Aug; 189():112908. PubMed ID: 37263896
[TBL] [Abstract][Full Text] [Related]
2. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
González-Martín A; Pothuri B; Vergote I; DePont Christensen R; Graybill W; Mirza MR; McCormick C; Lorusso D; Hoskins P; Freyer G; Baumann K; Jardon K; Redondo A; Moore RG; Vulsteke C; O'Cearbhaill RE; Lund B; Backes F; Barretina-Ginesta P; Haggerty AF; Rubio-Pérez MJ; Shahin MS; Mangili G; Bradley WH; Bruchim I; Sun K; Malinowska IA; Li Y; Gupta D; Monk BJ;
N Engl J Med; 2019 Dec; 381(25):2391-2402. PubMed ID: 31562799
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study.
O'Cearbhaill RE; Pérez-Fidalgo JA; Monk BJ; Tusquets I; McCormick C; Fuentes J; Moore RG; Vulsteke C; Shahin MS; Forget F; Bradley WH; Hietanen S; O'Malley DM; Dørum A; Slomovitz BM; Baumann K; Selle F; Calvert PM; Artioli G; Levy T; Kumar A; Malinowska IA; Li Y; Gupta D; González-Martín A
Gynecol Oncol; 2022 Jul; 166(1):36-43. PubMed ID: 35550709
[TBL] [Abstract][Full Text] [Related]
4. Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial.
Barretina-Ginesta MP; Monk BJ; Han S; Pothuri B; Auranen A; Chase DM; Lorusso D; Anderson C; Abadie-Lacourtoisie S; Cloven N; Braicu EI; Amit A; Redondo A; Shah R; Kebede N; Hawkes C; Gupta D; Woodward T; O'Malley DM; González-Martín A
Ther Adv Med Oncol; 2022; 14():17588359221126149. PubMed ID: 36172173
[TBL] [Abstract][Full Text] [Related]
5. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial.
Oza AM; Matulonis UA; Malander S; Hudgens S; Sehouli J; Del Campo JM; Berton-Rigaud D; Banerjee S; Scambia G; Berek JS; Lund B; Tinker AV; Hilpert F; Vázquez IP; D'Hondt V; Benigno B; Provencher D; Buscema J; Agarwal S; Mirza MR
Lancet Oncol; 2018 Aug; 19(8):1117-1125. PubMed ID: 30026000
[TBL] [Abstract][Full Text] [Related]
6. Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial.
Li N; Zhu J; Yin R; Wang J; Pan L; Kong B; Zheng H; Liu J; Wu X; Wang L; Huang Y; Wang K; Zou D; Zhao H; Wang C; Lu W; Lin A; Lou G; Li G; Qu P; Yang H; Zhang Y; Cai H; Pan Y; Hao M; Liu Z; Cui H; Yang Y; Yao S; Zhen X; Hang W; Hou J; Wang J; Wu L
JAMA Oncol; 2023 Sep; 9(9):1230-1237. PubMed ID: 37440217
[TBL] [Abstract][Full Text] [Related]
7. Homologous Recombination Deficiency Testing to Inform Patient Decisions About Niraparib Maintenance Therapy for High-Grade Serous or Endometrioid Epithelial Ovarian Cancer: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2023; 23(5):1-188. PubMed ID: 37637244
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.
Mirza MR; Benigno B; Dørum A; Mahner S; Bessette P; Barceló IB; Berton-Rigaud D; Ledermann JA; Rimel BJ; Herrstedt J; Lau S; du Bois A; Herráez AC; Kalbacher E; Buscema J; Lorusso D; Vergote I; Levy T; Wang P; de Jong FA; Gupta D; Matulonis UA
Gynecol Oncol; 2020 Nov; 159(2):442-448. PubMed ID: 32981695
[TBL] [Abstract][Full Text] [Related]
9. Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
Mirza MR; González-Martín A; Graybill WS; O'Malley DM; Gaba L; Stephanie Yap OW; Guerra EM; Rose PG; Baurain JF; Ghamande SA; Denys H; Prendergast E; Pisano C; Follana P; Baumann K; Calvert PM; Korach J; Li Y; Malinowska IA; Gupta D; Monk BJ
Cancer; 2023 Jun; 129(12):1846-1855. PubMed ID: 37060236
[TBL] [Abstract][Full Text] [Related]
10. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
Mirza MR; Åvall Lundqvist E; Birrer MJ; dePont Christensen R; Nyvang GB; Malander S; Anttila M; Werner TL; Lund B; Lindahl G; Hietanen S; Peen U; Dimoula M; Roed H; Ør Knudsen A; Staff S; Krog Vistisen A; Bjørge L; Mäenpää JU;
Lancet Oncol; 2019 Oct; 20(10):1409-1419. PubMed ID: 31474354
[TBL] [Abstract][Full Text] [Related]
11. Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer.
Lee A
Target Oncol; 2021 Nov; 16(6):839-845. PubMed ID: 34635996
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial.
Fabbro M; Moore KN; Dørum A; Tinker AV; Mahner S; Bover I; Banerjee S; Tognon G; Goffin F; Shapira-Frommer R; Wenham RM; Hellman K; Provencher D; Harter P; Vázquez IP; Follana P; Pineda MJ; Mirza MR; Hazard SJ; Matulonis UA
Gynecol Oncol; 2019 Mar; 152(3):560-567. PubMed ID: 30638768
[TBL] [Abstract][Full Text] [Related]
13. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.
Banerjee S; Moore KN; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Oza A; González-Martín A; Aghajanian C; Bradley WH; Holmes E; Lowe ES; DiSilvestro P
Lancet Oncol; 2021 Dec; 22(12):1721-1731. PubMed ID: 34715071
[TBL] [Abstract][Full Text] [Related]
14. Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial.
Aghajanian C; Bookman MA; Fleming GF; Swisher EM; Steffensen KD; Friedlander M; Okamoto A; Jackson CG; Sullivan D; Ratajczak CK; Coleman RL
Gynecol Oncol; 2021 Aug; 162(2):375-381. PubMed ID: 34112513
[TBL] [Abstract][Full Text] [Related]
15. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Moore KN; Secord AA; Geller MA; Miller DS; Cloven N; Fleming GF; Wahner Hendrickson AE; Azodi M; DiSilvestro P; Oza AM; Cristea M; Berek JS; Chan JK; Rimel BJ; Matei DE; Li Y; Sun K; Luptakova K; Matulonis UA; Monk BJ
Lancet Oncol; 2019 May; 20(5):636-648. PubMed ID: 30948273
[TBL] [Abstract][Full Text] [Related]
16. OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab.
Hardesty MM; Krivak TC; Wright GS; Hamilton E; Fleming EL; Belotte J; Keeton EK; Wang P; Gupta D; Clements A; Gray HJ; Konecny GE; Moore RG; Richardson DL
Gynecol Oncol; 2022 Aug; 166(2):219-229. PubMed ID: 35690498
[TBL] [Abstract][Full Text] [Related]
17. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
Mirza MR; Monk BJ; Herrstedt J; Oza AM; Mahner S; Redondo A; Fabbro M; Ledermann JA; Lorusso D; Vergote I; Ben-Baruch NE; Marth C; Mądry R; Christensen RD; Berek JS; Dørum A; Tinker AV; du Bois A; González-Martín A; Follana P; Benigno B; Rosenberg P; Gilbert L; Rimel BJ; Buscema J; Balser JP; Agarwal S; Matulonis UA;
N Engl J Med; 2016 Dec; 375(22):2154-2164. PubMed ID: 27717299
[TBL] [Abstract][Full Text] [Related]
18. Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial.
Belotte J; Felicetti B; Baines AJ; YoussefAgha A; Rojas-Espaillat L; Ortiz AG; Provencher D; Vázquez RM; Cortijo LG; Zeng X
Trials; 2024 May; 25(1):301. PubMed ID: 38702828
[TBL] [Abstract][Full Text] [Related]
19. Optimizing disease progression assessment using blinded central independent review and comparing it with investigator assessment in the PRIMA/ENGOT-ov26/GOG-3012 trial: challenges and solutions.
Herzog TJ; Wahab SA; Mirza MR; Pothuri B; Vergote I; Graybill WS; Malinowska IA; York W; Hurteau JA; Gupta D; González-Martin A; Monk BJ
Int J Gynecol Cancer; 2023 Nov; 33(11):1733-1742. PubMed ID: 37931976
[TBL] [Abstract][Full Text] [Related]
20. Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - a plain language summary.
González-Martín A; Pothuri B; Vergote I; Graybill W; Lorusso D; McCormick CC; Freyer G; Backes F; Heitz F; Redondo A; Moore RG; Vulsteke C; O'Cearbhaill RE; Malinowska IA; Shtessel L; Compton N; Mirza MR; Monk BJ
Future Oncol; 2024 Mar; ():. PubMed ID: 38501262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
